Clinical Trial Update: Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of talazoparib in patients with advanced or metastatic solid tumors unsuitable for surgery and with liver or kidney dysfunction has bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
• Small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Talzenna (talazoparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: WITHDRAWN